Renal & Urology News

1 week ago | renalandurologynews.com | Ryner Lai

The presence of renal hyperfiltration (RHF), whether it persists or disappears over time, is associated with increased risks of cardiovascular events and all-cause mortality, according to a poster presentation at the 62nd European Renal Association (ERA) Congress in Vienna, Austria. RHF that develops, then disappears is also linked with progression to kidney failure. Previous cross-sectional studies have linked RHF to poor clinical outcomes.

1 week ago | renalandurologynews.com | Jessica Nye

Spironolactone does not lower risk for cardiovascular (CV) mortality and heart failure (HF) hospitalization among patients receiving maintenance dialysis. These phase 3 trial findings were presented by Michael Walsh, MD, PhD, of McMaster University in Hamilton, Ontario, during a late-breaking trial session at the 62nd European Renal Association (ERA) congress in Vienna, Austria.

1 week ago | renalandurologynews.com | natasha persaud

An acellular tissue engineered vessel (ATEV™) provides better functional patency and usability for hemodialysis vascular access than an autologous arteriovenous fistula (AVF) in women in general and men with obesity and diabetes — patients at high-risk for vascular access maturation failure. An investigator presented results from a secondary analysis of a pivotal phase 3 clinical trial at the Society for Vascular Surgery vascular annual meeting (VAM25) in New Orleans, Louisiana.

1 week ago | renalandurologynews.com | Jessica Nye

The monoclonal antibody MK-2060 does not meaningfully lower arteriovenous graft (AVG) thrombosis among patients with end-stage kidney disease (ESKD) on hemodialysis. Wolfgang Winkelmayer, MD, MPH, ScD, of Baylor College of Medicine in Houston, Texas, presented the phase 2 trial finding during a late-breaking abstract session at the 62nd European Renal Association (ERA) congress in Vienna, Austria.

2 weeks ago | renalandurologynews.com | natasha persaud

The survival advantage of deceased-donor kidney transplantation does not apply to every patient and every donor organ, investigators revealed at the 62th European Renal Association (ERA) congress in Vienna, Austria. Older and higher-risk patients may live as long by remaining on dialysis.